Back to results
US 2007/0191429 A1Published application
Ppar activators
AssigneePfizer Inc.
InventorsScott Bagley, Thomas Brandt, Robert Dugger, William Hada, Cheryl Hayward, Zhengyu Liu
Life of this patent
Estimating the term…
Abstract
PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
Claims15
A compound of Formula I
- an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug;
- wherein m and n are each independently one or two;
- V and Y are each independently a) methylene, or b) carbonyl;
- F and G are each independently a) hydrogen, b) halo, c) (C1-C4)alkyl optionally substituted with one to nine fluoro, d) (C3-C6)cycloalkyl, e) hydroxy, f) (C1-C4)alkoxy or g) (C1-C4)alkylthio;
- X is a) -Z or b) -B-C(R1R2)-Z;
- B is a) oxy, b) thio, c) sulfinyl, d) sulfonyl, e) methylene, or f) —N(H)—;
- Z is a) —C(O)OH, b) —C(O)O—(C1-C4)alkyl, c) —C(O)O—(C0-C4)alkyl-aryl, d) —C(O)—NH2, e) hydroxyaminocarbonyl, f) tetrazolyl, g) tetrazolylaminocarbonyl, h) 4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl, i) 3-oxoisoxazolidin-4-yl-aminocarbonyl, j) —C(O)N(H)SO2R4, or k) —NHSO2R4;
- wherein R4 is a) (C1-C6)alkyl, b) amino or c) mono-N— or di-N,N—(C1-C6)alkylamino, wherein the (C1-C6)alkyl substitutents in R4 are optionally independently substituted with one to nine fluoro;
- R1 is a) H, b) (C1-C4)alkyl, or c) (C3-C6)cycloalkyl;
- R2 is a) H, b) (C3-C6)cycloalkyl or c) a fully or partially saturated or fully unsaturated one to four membered straight or branched carbon chain;
- wherein the carbon(s) in the carbon chain may optionally be replaced with one or two heteroatoms selected independently from oxygen and sulfur;
- and wherein the sulfur is optionally mono- or di-substituted with oxo;
- wherein the carbon(s) in the carbon chain in R2 is optionally independently substituted as follows:
- a) the carbon(s) is optionally mono-, di- or tri-substituted independently with halo, b) the carbon(s) is optionally mono-substituted with hydroxy or (C1-C4)alkoxy, and c) the carbon(s) is optionally mono-substituted with oxo;
- and
- wherein the carbon(s) in the carbon chain in R2 is optionally mono-substituted with Q;
- wherein Q is a partially or fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or is a bicyclic ring consisting of two fused partially or fully saturated or fully unsaturated three to six membered rings, taken independently;
- wherein the bicyclic ring optionally has one to four heteroatoms selected independently from oxygen, sulfur and nitrogen;
- wherein the Q ring is optionally mono-, di- or tri-substituted independently with a) halo, b) (C2-C6)alkenyl, c) (C1-C6) alkyl, d) hydroxy, e) (C1-C6)alkoxy, f) (C1-C4)alkylthio, g) amino, h) nitro, i) cyano, j) oxo, k) carboxy, l) (C1-C6)alkyloxycarbonyl, or m) mono-N— or di-N,N—(C1-C6)alkylamino;
- wherein the (C1-C6)alkyl and (C1-C6)alkoxy substitutents on the Q ring is optionally mono-, di- or tri-substituted independently with a) halo, b) hydroxy, c) (C1-C6)alkoxy, d) (C1-C4)alkylthio, e) amino, f) nitro, g) cyano, h) oxo, i) carboxy, j) (C1-C6)alkyloxycarbonyl, or k) mono-N— or di-N,N—(C1-C6)alkylamino;
- wherein the (C1-C6)alkyl substitutent is on the Q ring is also optionally substituted with one to nine fluoro;
- or wherein R1 and R2 are linked together to form a three to six membered fully saturated carbocyclic ring, optionally having one heteroatom selected from oxygen, sulfur and nitrogen to form a heterocyclic ring;
- E is a) carbonyl, b) sulfonyl, or c) methylene;
- W is a) a bond, b) carbonyl, c) —N(H)—, d) —N((C1-C4)alkyl)-, e) (C2-C8)alkenyl, f) oxy, g) —(C1-C4)alkyl-O—, h) —NH—(C1-C4)alkyl-, or i) —(C1-C6)alkyl-;
- wherein the (C1-C6)alkyl and the (C2-C8)alkenyl groups in W may optionally be mono- or di-substituted independently with a) oxo, b) halo, c) (C1-C6)alkoxycarbonyl, d) (C1-C6)alkyl, e) (C2-C6)alkenyl, f) (C3-C7)cycloalkyl, g) hydroxy, h) (C1-C6)alkoxy, i) (C1-C4)alkylthio, j) amino, k) cyano, l) nitro, m) mono-N— or di-N,N—(C1-C6)alkylamino, or n) —NH—(C1-C)alkylamino;
- or wherein W is CR7R8 wherein R7 and R8 are linked together to form a three to six membered fully saturated carbocyclic ring;
- A is a) mono-N— or di-N,N—(C1-C6)alkylamino, b) (C2-C6)alkanoylamino, c) (C1-C6)alkoxy, d) a partially or fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or e) a bicyclic ring consisting of two fused partially or fully saturated or fully unsaturated three to six membered rings, taken independently;
- wherein the bicyclic ring optionally has one to four heteroatoms selected independently from oxygen, sulfur and nitrogen;
- and
- wherein the A ring is optionally mono-, di- or tri-substituted independently with a) oxo, b) carboxy, c) halo, d) (C1-C6)alkoxycarbonyl, e) (C1-C6)alkyl, f) (C2-C6)alkenyl, g) (C3-C7)cycloalkyl, h) (C3-C7)cycloalkyl(C1-C6)alkyl, i) hydroxy, j) (C1-C6)alkoxy, k) (C1-C4)alkylthio, l) (C1-C4)alkylsulfonyl, m) amino, n) cyano, o) nitro, or p) mono-N— or di-N,N—(C1-C6)alkylamino;
- wherein the (C1-C6)alkyl and (C1-C6)alkoxy substitutents on the A ring are also optionally mono-, di- or tri-substituted independently with a) halo, b) hydroxy, c) (C1-C4)alkyl optionally substituted with one to nine fluoro, d) (C3-C6)cycloalkyl, e) (C1-C6)alkoxy, f) amino, or g) mono-N— or di-N,N—(C1-C6)alkylamino;
- or wherein the A ring is optionally mono-substituted with a partially or fully saturated or fully unsaturated three to eight membered ring, optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen;
- also wherein this three to eight membered ring is optionally mono-, di- or tri-substituted independently with a) halo, b) hydroxy, c) (C1-C4)alkyl optionally substituted with one to nine fluoro, d) (C3-C6)cycloalkyl, e) (C1-C6)alkoxy, f) amino, g) mono-N— or di-N,N—(C1-C6)alkylamino, or h) (C1-C4)alkylthio;
- provided that:
- when V and Y are each methylene and m and n are each one forming a six-membered piperidinyl ring, this ring is substituted by the phenyl ring (designated as J) at other than the 4-position;
- and
- when E is carbonyl, W is a bond and X is -B-C(R1R2)-Z wherein R1 and R2 are each hydrogen, B is —O— or —N(H)—, and Z is —C(O)OH or —C(O)O—(C1-C4)alkyl, then one of F or G must be a) —(C1-C4)alkyl, b) (C3-C6)cycloalkyl, c) (C1-C4)alkoxy or d) (C1-C4)alkylthio.
34 more elements
Dependencies are inferred from the claim text.